ATE158283T1 - Hypolipidämische, kondensierte 1,4-thiazepine - Google Patents

Hypolipidämische, kondensierte 1,4-thiazepine

Info

Publication number: ATE158283T1
Authority: AT; Austria
Prior art keywords: carbon atoms; 6alkyl; independently selected; hydrogen; pct
Prior art date: 1993-02-15

Application number

AT94906323T

Other languages

English (en)

Inventor

Lawrence Edward Brieaddy

Gordon Lewis Hodgson Jr

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-15

Filing date

1994-02-15

Publication date

1997-10-15

1993-02-15 Priority claimed from GB939303014A external-priority patent/GB9303014D0/en

1993-07-22 Priority claimed from GB939315154A external-priority patent/GB9315154D0/en

1994-02-15 Application filed by Wellcome Found filed Critical Wellcome Found

1997-10-15 Application granted granted Critical

1997-10-15 Publication of ATE158283T1 publication Critical patent/ATE158283T1/de

Links

230000000055 hyoplipidemic effect Effects 0.000 title abstract 2
150000004915 1,4-thiazepines Chemical class 0.000 title 1
125000004432 carbon atom Chemical group C* 0.000 abstract 7
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
125000000753 cycloalkyl group Chemical group 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
229910052739 hydrogen Inorganic materials 0.000 abstract 4
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
239000005864 Sulphur Substances 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
125000005842 heteroatom Chemical group 0.000 abstract 2
229910052757 nitrogen Inorganic materials 0.000 abstract 2
239000001301 oxygen Substances 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical group S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 abstract 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
239000003613 bile acid Substances 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000001624 naphthyl group Chemical group 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
-1 pyrryl Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

AT94906323T 1993-02-15 1994-02-15 Hypolipidämische, kondensierte 1,4-thiazepine ATE158283T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB939303014A GB9303014D0 (en)	1993-02-15	1993-02-15	Hypolipidaemic compounds
GB939315154A GB9315154D0 (en)	1993-07-22	1993-07-22	Hypolipademic compounds

Publications (1)

Publication Number	Publication Date
ATE158283T1 true ATE158283T1 (de)	1997-10-15

Family

ID=26302466

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94906323T ATE158283T1 (de)	1993-02-15	1994-02-15	Hypolipidämische, kondensierte 1,4-thiazepine

Country Status (14)

Country	Link
US (1)	US5817652A (de)
EP (1)	EP0683773B1 (de)
JP (1)	JPH08507049A (de)
AT (1)	ATE158283T1 (de)
AU (1)	AU6007794A (de)
CA (1)	CA2156184A1 (de)
DE (1)	DE69405714T2 (de)
DK (1)	DK0683773T3 (de)
ES (1)	ES2109672T3 (de)
GR (1)	GR3025532T3 (de)
HU (1)	HUT71613A (de)
IL (1)	IL108634A0 (de)
TW (1)	TW342388B (de)
WO (1)	WO1994018183A1 (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA956647B (en) *	1994-08-10	1997-02-10	Wellcome Found	Hypolipidaemic compounds.
US5994391A (en) *	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6107494A (en) *	1994-09-13	2000-08-22	G.D. Searle And Company	Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en)	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en) *	1994-11-17	1995-01-04	Wellcom Foundation The Limited	Hypolipidemic benzothiazepines
ATE242258T1 (de) *	1997-03-14	2003-06-15	Aventis Pharma Gmbh	Hypolipidemische 1,4-benzothiazepin-1,1-dioxide
JPH11193289A (ja) *	1997-12-26	1999-07-21	Suntory Ltd	ピロールスルホンアミド誘導体
US6458850B1 (en)	1998-12-23	2002-10-01	G.D. Searle, Llc	Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
BR9916486A (pt)	1998-12-23	2002-02-05	Searle Llc	Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
AU2157500A (en)	1998-12-23	2000-07-31	G.D. Searle Llc	Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
EA004877B1 (ru)	1998-12-23	2004-08-26	Джи.Ди.Сирл Ллс	Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
DK1140189T3 (da)	1998-12-23	2003-09-15	Searle Llc	Kombinationer af ileal galdesyre-transportinhibitorer og fibrinsyrederivater til cardiovaskulære indikationer
AU3103800A (en)	1998-12-23	2000-07-31	G.D. Searle Llc	Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
AU2157400A (en)	1998-12-23	2000-07-31	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
DE19916108C1 (de) *	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
GB9914745D0 (en) *	1999-06-24	1999-08-25	Knoll Ag	Therapeutic agents
EP1207882A4 (de) *	1999-07-30	2003-03-19	Vertex Pharma	Azyklische und zyklische aminderivate
JP2001196581A (ja) *	2000-01-17	2001-07-19	Oki Electric Ind Co Ltd	半導体装置および半導体装置の製造方法
SE0000772D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
EP1286984A2 (de)	2000-03-10	2003-03-05	Pharmacia Corporation	Verfahren zur herstellung von tetrahydrobenzothiepinen
US7312044B2 (en)	2003-03-07	2007-12-25	The Trustees Of Columbia University In The City Of New York	Type 1 ryanodine receptor-based methods
US7879840B2 (en)	2005-08-25	2011-02-01	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en)	2000-05-10	2008-07-01	The Trustees Of Columbia University In The City Of New York	Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en)	2000-05-10	2011-09-20	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en)	2004-01-22	2010-05-18	The Trustees Of Columbia University In The City Of New York	Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20020183307A1 (en) *	2000-07-26	2002-12-05	Tremont Samuel J.	Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
EG26979A (en)	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
MY131995A (en)	2001-09-08	2007-09-28	Astrazeneca Ab	Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
BR0213501A (pt)	2001-11-02	2004-08-24	Searle Llc	Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
MXPA04006255A (es)	2002-01-17	2004-09-27	Pharmacia Corp	Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en)	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
WO2004020421A1 (ja)	2002-08-28	2004-03-11	Asahi Kasei Pharma Corporation	新規な４級アンモニウム化合物
US7312208B2 (en)	2002-08-28	2007-12-25	Asahi Kasei Pharma Corporation	Quaternary ammonium compounds
US7544678B2 (en)	2002-11-05	2009-06-09	The Trustees Of Columbia University In The City Of New York	Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308351A1 (de)	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
EP2428516A1 (de)	2003-11-19	2012-03-14	Metabasis Therapeutics, Inc.	Neue Phosphor enthaltende Thyromimetika
US8710045B2 (en)	2004-01-22	2014-04-29	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7241787B2 (en)	2004-01-25	2007-07-10	Sanofi-Aventis Deutschland Gmbh	Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
AU2005217318B2 (en) *	2004-02-27	2010-07-01	Asahi Kasei Pharma Corporation	Novel benzothiazepine and benzothiepine compounds
EP1586573B1 (de)	2004-04-01	2007-02-07	Sanofi-Aventis Deutschland GmbH	Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
US7704990B2 (en)	2005-08-25	2010-04-27	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
EA028108B1 (ru) *	2008-03-03	2017-10-31	Армго Фарма, Инк.	Способ получения бензотиазепинов из гамма-аминоалкилбензолов
WO2010018686A1 (ja) *	2008-08-12	2010-02-18	日本曹達株式会社	含窒素ヘテロ環誘導体および農園芸用殺菌剤
CA2739901A1 (en) *	2008-10-17	2010-04-22	Akaal Pharma Pty Ltd	S1p receptors modulators
EP2367554A4 (de) *	2008-11-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Gallensäurerückflusshemmer zur behandlung von adipositas und diabetes
WO2010093601A1 (en)	2009-02-10	2010-08-19	Metabasis Therapeutics, Inc.	Novel sulfonic acid-containing thyromimetics, and methods for their use
KR101435729B1 (ko) *	2009-09-28	2014-09-01	닛뽕소다 가부시키가이샤	함질소 헤테로 고리 화합물 및 그의 염, 그리고 농원예용 살균제
JP2011162472A (ja) *	2010-02-09	2011-08-25	Nippon Soda Co Ltd	含窒素ヘテロ環化合物またはその塩、ならびに農園芸用殺菌剤
JO3131B1 (ar)	2010-04-27	2017-09-20	Glaxosmithkline Llc	مركبات كيميائية
EP4137137A1 (de)	2010-05-26	2023-02-22	Satiogen Pharmaceuticals, Inc.	Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
MX366925B (es)	2010-11-04	2019-07-31	Albireo Ab	Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en)	2010-11-08	2013-09-12	Albireo Ab	Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EA038594B1 (ru)	2011-10-28	2021-09-21	Шайр Хьюман Дженетик Терапис, Инк.	Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja)	2011-10-28	2017-10-25	ルメナファーマシューティカルズエルエルシー	小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
AU2014229050A1 (en)	2013-03-15	2015-10-22	Lumena Pharmaceuticals Llc	Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
KR20160002773A (ko)	2013-03-15	2016-01-08	루메나 파마수티컬즈, 인코포레이티드	원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
JO3301B1 (ar)	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en)	2014-06-25	2015-12-30	Ea Pharma Co., Ltd.	Solid formulation and method for preventing or reducing coloration thereof
JP6543330B2 (ja)	2014-08-05	2019-07-10	グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙ（Ｎｏ．２）Ｌｉｍｉｔｅｄ	ベンゾジアゼピンの合成
EP3012252A1 (de)	2014-10-24	2016-04-27	Ferring BV	Kristalline Form von elobixibat
WO2016109596A1 (en) *	2014-12-30	2016-07-07	Myotherix, Inc.	Novel calcium modulators
CN108601744B (zh)	2016-02-09	2022-01-04	阿尔比里奥公司	口服考来烯胺制剂及其用途
JP6954927B2 (ja)	2016-02-09	2021-10-27	アルビレオ・アクチボラグ	経口コレスチラミン製剤及びその使用
CA3011595C (en)	2016-02-09	2024-01-02	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
JP7328207B2 (ja)	2017-08-09	2023-08-16	アルビレオ・アクチボラグ	コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
CN111032019B (zh)	2017-08-09	2022-07-05	阿尔比里奥公司	考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7391048B2 (ja)	2018-06-05	2023-12-04	アルビレオ・アクチボラグ	ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
KR20210024033A (ko)	2018-06-20	2021-03-04	알비레오 에이비	오데빅시바트의 약학 제제
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
SG11202108566VA (en)	2019-02-06	2021-09-29	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
CN113453753B (zh)	2019-02-06	2024-07-23	阿尔比里奥公司	苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
EP4424363B1 (de)	2019-02-12	2026-04-29	Mirum Pharmaceuticals, Inc.	Verfahren zur wachstumssteigerung bei pädiatrischen patienten mit cholestatischer lebererkrankung
WO2021110885A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
JP7665621B2 (ja)	2019-12-04	2025-04-21	アルビレオ・アクチボラグ	ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158181A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158195A1 (en)	2019-12-04	2021-06-10	Per-Goran Gillberg	Benzothia(di)azepine compounds and their use as bile acid modulators
CN114786772B (zh)	2019-12-04	2024-04-09	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
ES3002777T3 (en)	2020-08-03	2025-03-07	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en)	2020-11-12	2023-06-08	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt)	2020-12-04	2023-10-03	Albireo Ab	Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh)	2021-06-03	2024-01-16	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4536232A1 (de)	2022-06-09	2025-04-16	Albireo AB	Behandlung von hepatitis
CN119487013A (zh)	2022-07-05	2025-02-18	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4629997A1 (de)	2022-12-09	2025-10-15	Albireo AB	Asbt-hemmer bei der behandlung von nierenerkrankungen
WO2025146507A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3362962A (en) *	1964-01-24	1968-01-09	Hoffmann La Roche	Certain benzothiazepine derivatives
US4778791A (en) *	1986-05-16	1988-10-18	Tanabe Seiyaku Co., Ltd.	Pharmaceutical composition for improving constitution of lipids in blood
GB9203347D0 (en) *	1992-02-17	1992-04-01	Wellcome Found	Hypolipidaemic compounds
US5276025A (en) *	1992-09-09	1994-01-04	Merck & Co., Inc.	Heterobicyclic sulfonamides

1994
- 1994-02-14 IL IL10863494A patent/IL108634A0/xx unknown
- 1994-02-15 CA CA002156184A patent/CA2156184A1/en not_active Abandoned
- 1994-02-15 DE DE69405714T patent/DE69405714T2/de not_active Expired - Fee Related
- 1994-02-15 AT AT94906323T patent/ATE158283T1/de active
- 1994-02-15 DK DK94906323.4T patent/DK0683773T3/da active
- 1994-02-15 EP EP94906323A patent/EP0683773B1/de not_active Expired - Lifetime
- 1994-02-15 WO PCT/GB1994/000299 patent/WO1994018183A1/en not_active Ceased
- 1994-02-15 AU AU60077/94A patent/AU6007794A/en not_active Abandoned
- 1994-02-15 HU HU9501808A patent/HUT71613A/hu unknown
- 1994-02-15 ES ES94906323T patent/ES2109672T3/es not_active Expired - Lifetime
- 1994-02-15 JP JP6517844A patent/JPH08507049A/ja not_active Ceased
- 1994-02-15 US US08/505,232 patent/US5817652A/en not_active Expired - Fee Related
- 1994-02-25 TW TW083101603A patent/TW342388B/zh active
1997
- 1997-11-27 GR GR970403181T patent/GR3025532T3/el unknown

Also Published As

Publication number	Publication date
WO1994018183A1 (en)	1994-08-18
US5817652A (en)	1998-10-06
JPH08507049A (ja)	1996-07-30
AU6007794A (en)	1994-08-29
CA2156184A1 (en)	1994-08-18
IL108634A0 (en)	1994-05-30
DE69405714T2 (de)	1998-01-29
HU9501808D0 (en)	1995-08-28
ES2109672T3 (es)	1998-01-16
DK0683773T3 (da)	1998-02-16
EP0683773B1 (de)	1997-09-17
TW342388B (en)	1998-10-11
EP0683773A1 (de)	1995-11-29
HUT71613A (en)	1996-01-29
DE69405714D1 (de)	1997-10-23
GR3025532T3 (en)	1998-02-27

Publication	Publication Date	Title
DE69405714D1 (de)	1997-10-23	Hypolipidämische, kondensierte 1,4-thiazepine
PH30921A (en)	1997-12-23	Branched alkylamino derivatives of thiazole, processes for their preparation and pharmaceutical composition containing them.
ATE250622T1 (de)	2003-10-15	4'-c-ethynyl-pyrimidine nukleoside
AU4396899A (en)	2000-01-24	Remedies for diabetes
DK0874812T3 (da)	2000-09-11	Hidtil ukendte 2,3,5-trimethyl-4-hydroxyanilidderivater, fremstilling deraf og terapeutisk anvendelse deraf
TW243449B (de)	1995-03-21
NZ324447A (en)	1999-08-30	1-methyl-carbapenem substituted by a 4-pyrrolidinylthio group and medicaments
DK0420121T3 (da)	1993-05-03	Antitumormiddel
CA2014521A1 (en)	1990-10-15	2-Substituted N,N'-Ditrimethoxybenzoyl Piperazines, a Preparation Process of the Same and Therapeutic Compositions Containing Them
ATE173471T1 (de)	1998-12-15	Pyridazinonderivate oder deren salze, verfahren zu ihrer herstellung und diese enthaltende antischockmittel
DK0635495T3 (da)	1999-06-14	Benzospiroalkenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende dem
IL148196A0 (en)	2002-09-12	Heterocyclic compounds and pharmaceutical compositions containing the same
ES2084120T3 (es)	1996-05-01	Medicamentos para prevenir y tratar enfermedades del aparato circulatorio que contienen compuestos de espiro-3-heteroazolidina.
DK0420224T3 (da)	1993-04-05	Anthihepatopatisk middel
KR930019683A (ko)	1993-10-18	사이클릭 아미노메틸렌 비스포스포네이트 유도체
EA200001157A2 (ru)	2001-06-25	Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
DE69409877D1 (de)	1998-06-04	Benzospiroalken-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen